Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palbociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 20/20 | 1.00 |
| ▸ | CCND1 known ✓ | P24385 | 16/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 5/20 | 0.98 |
| ▸ | CCND3 | P30281 | 13/20 | 0.98 |
| ▸ | CCND2 | P30279 | 12/20 | 0.98 |
| ▸ | CDK2 | P24941 | 5/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.98 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.98 |
| ▸ | CDK9 | P50750 | 2/20 | 0.98 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.98 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.98 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.98 |
| ▸ | STK16 | O75716 | 1/20 | 0.98 |
| ▸ | CCNK | O75909 | 1/20 | 0.98 |
| ▸ | PDE5A | O76074 | 1/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palbociclib SCHEMBL29425547 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29387795 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29379411 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29362383 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL462630 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL30584526 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Hydrochloric Acid SCHEMBL4828453 | 0.98 | CDK4 (0.98) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL28567292 | 0.98 | CDK4 (0.97) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL4827183 | 0.97 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL30176561 | 0.97 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017021177-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITAT DE BARCELONA (ES) | 2017-02-09 | — | — | WO | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| EP-2925859-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Takara Bio Europe AB (SE) | 2015-10-07 | — | — | EP | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| WO-2014083132-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CELLECTIS SA (FR) | 2014-06-05 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025262235-A1 | UNGULATE PLURIPOTENT STEM CELL CULTURE MEDIUM | MEAT TOMORROW APS (DK) | 2025-12-26 | — | — | WO | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-117899085-A | Pharmaceutical composition and pharmaceutical preparation for improving success rate of full-thickness skin grafting and application thereof | 无锡市南京大学锡山应用生物技术研究所 | 2024-04-19 | — | — | CN | disclosed |
| CN-117866991-A | Chimeric antigen receptor for the treatment of cancer | 诺华股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114181905-B | Exosome easy to penetrate blood brain barrier | 南京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| US-20050059670-A1 | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a preferential cyclin-dependent kinase 4 (CDK4) inhibitor, used for treating inflammation and cell proliferative diseases such as cancer and restenosis | PFIZER INC | 2005-03-17 | — | — | US | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059670-A1 | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a preferential cyclin-dependent kinase 4 (CDK4) inhibitor, used for treating inflammation and cell proliferative diseases such as cancer and restenosis | CDK4, CDK5, CDK3 | CDK4 1/4885CCND1 24/4885CDK6 11/4885 |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CDK4 1/4885CCND1 27/4885CDK6 7/4885 |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 35/4885CDK6 7/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | CDK4 2900/4885CCND1 3834/4885CDK6 2206/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | CDK4 1064/4885CCND1 2954/4885CDK6 2798/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CDK4 1/4885CCND1 34/4885CDK6 8/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | CDK4 9/4885CCND1 125/4885CDK6 617/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | CDK4 7/4885CCND1 618/4885CDK6 11/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | CDK4 1/4885CCND1 66/4885CDK6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.